Hepatocyte Surface Engineering for Improved Post-transplant Viability

Information

  • Research Project
  • 10114711
  • ApplicationId
    10114711
  • Core Project Number
    R15DK127340
  • Full Project Number
    1R15DK127340-01
  • Serial Number
    127340
  • FOA Number
    PAR-18-714
  • Sub Project Id
  • Project Start Date
    9/15/2020 - 4 years ago
  • Project End Date
    8/31/2022 - 2 years ago
  • Program Officer Name
    SHERKER, AVERELL H
  • Budget Start Date
    9/15/2020 - 4 years ago
  • Budget End Date
    8/31/2021 - 3 years ago
  • Fiscal Year
    2020
  • Support Year
    01
  • Suffix
  • Award Notice Date
    9/14/2020 - 4 years ago
Organizations

Hepatocyte Surface Engineering for Improved Post-transplant Viability

Project Summary/Abstract Hepatocyte Surface Engineering for Improved Post-transplant Viability The long term objective of our research is to demonstrate the significant potential of covalently-modified live cells or tissues in biomedical applications. The chemical modification of biological surfaces can be utilized to attenuate or enhance native characteristics or to endow these substrates with novel capabilities. We believe that covalently- modified cells can provide a unique therapeutic advantage in cell transplantation, and have reported covalently- modified drug-eluting pancreatic islets exhibiting superior survival and engraftment in a murine model of islet transplantation. We have recently demonstrated several effective methods for the covalent modification of primary rodent and human hepatocytes that provide durable conjugates while retaining cell viability and functionality. In this proposal, we describe experiments focused on altering the characteristics of primary hepatocytes using three distinct strategies: by installing surface camouflage to minimize juxtracrine signaling; by incorporating specific signaling molecules to promote enhanced/altered juxtracrine signaling; and by conjugating small-molecule therapeutics designed for slow release, pharmacologically promoting a localized advantageous effect. It is anticipated that the studies described herein will provide insights into the most promising strategies for enhancing cell survival in hepatocyte transplantation, and future work will be focused on developing those methods further towards application in the clinic. Additionally, these experiments are designed to be foundational studies, enabling future work exploring the surface chemistry of other cells or tissues with promise in transplantation or therapy, investigating different platforms for surface camouflage or different compounds and pathways for juxtracrine signaling, and evaluating alternative bioactive small-molecules with a wide array of targets. In addition to being an innovative research project, the proposed project will significantly enhance the biomedical research environment at Baylor University, an undergraduate-focused institution. Immersed in an integrated interdisciplinary biomedical research project where they participate in both the basic and the translational aspects of a research project, these undergraduate researchers will gain experience as part of a very collaborative team, helping them to gain a greater appreciation for the significance of the many diverse components of the biomedical research enterprise. The overall research hypothesis is that the ex vivo covalent modification of hepatocytes prior to transplantation represents a general strategy for providing cell-surface camouflage as well as the localized and sustained delivery of potent small molecule drugs, and that this strategy can be implemented to significantly reduce early acute cell loss and inflammation and improve engraftment in a hepatocyte transplantation model. The following specific aims are proposed: 1. Hepatocytes with dense PEG surface-camouflage will be prepared and characterized 2. Hepatocytes with covalent CD-47 peptide surface-modification will be prepared and characterized 3. TAK-242-eluting hepatocytes will be prepared and characterized

IC Name
NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES
  • Activity
    R15
  • Administering IC
    DK
  • Application Type
    1
  • Direct Cost Amount
    334542
  • Indirect Cost Amount
    96455
  • Total Cost
    430997
  • Sub Project Total Cost
  • ARRA Funded
    False
  • CFDA Code
    847
  • Ed Inst. Type
    SCHOOLS OF ARTS AND SCIENCES
  • Funding ICs
    NIDDK:430997\
  • Funding Mechanism
    Non-SBIR/STTR RPGs
  • Study Section
    HBPP
  • Study Section Name
    Hepatobiliary Pathophysiology Study Section
  • Organization Name
    BAYLOR UNIVERSITY
  • Organization Department
    CHEMISTRY
  • Organization DUNS
    007516735
  • Organization City
    WACO
  • Organization State
    TX
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    767987360
  • Organization District
    UNITED STATES